Stryker Corporation (SYK) drops 5.2% after Q1 earnings miss
May 1, 20266 min read
Key Takeaway
Stryker Corporation (SYK) drops sharply after its Q1 2026 earnings report missed Wall Street expectations on both profit and revenue. The selloff reflects investor concern that a March cyber incident disrupted operations, slowed sales growth, and compressed margins, even though management left full-year guidance unchanged. For investors, the move signals a valuation reset rather than a broken business, but execution must improve quickly to justify SYK’s premium multiple.
Stryker Corporation (SYK) drops sharply today, down 5.21% to $298.7101 as of 3:04 p.m. ET, while volume runs at 1.4x its 200-day average. The selloff stands out because the broader market is higher, which points the finger at company-specific news rather than a sector-wide risk-off move.
Key Takeaways
SYK is sliding after its April 30 Q1 2026 earnings report, with the stock down 5.21% on above-average volume.
The main catalyst is a clear earnings miss: adjusted EPS came in at $2.60 versus a $2.98 consensus estimate, while revenue of $6.02B missed estimates by 4.4%.
A March cyber incident disrupted operations and weighed on Q1 sales growth, which slowed to 2.6% year over year.
Stryker kept full-year guidance intact at 8.0%-9.5% organic sales growth and adjusted EPS of $14.90-$15.10, but investors are demanding proof that the lost sales will be recovered.
With a P/E near 37.47, SYK still carries a premium multiple, so even a temporary execution stumble can trigger a fast valuation reset.
Why Stryker Corporation Stock Is Dropping After Q1 Earnings
The cleanest explanation for today’s move is Stryker’s first-quarter earnings report. The company posted adjusted EPS of $2.60, missing the $2.98 consensus by 12.8%. Revenue was $6.02B, up 2.6% year over year, but still 4.4% below consensus.
That kind of miss matters more when a stock trades at a premium. SYK entered the print with a reputation for steady execution, so a quarter that came in light on both sales and earnings was enough to knock confidence off balance.
Importantly, this was not just a headline EPS issue. The quarter showed uneven demand and disruption across the business. U.S. sales rose only 0.8%, while international sales increased 8.3% on a reported basis and 1.5% on a constant-currency basis. MedSurg and Neurotechnology grew 5.0%, but Orthopaedics was nearly flat at 0.1%.
Analysts also moved quickly after the report. On May 1, Bernstein cut its price target to $410 from $465, Baird cut its target to $385 from $437, Needham lowered its target to $418 from $454, BTIG trimmed its target to $379 from $397, Evercore ISI cut to $355 from $365, and Deutsche Bank slashed its target to $315 from $402. Those are not downgrades in name, but they reinforce the same message: the quarter damaged near-term confidence.
How the March Cyber Incident Hit Stryker's Quarterly Results
The operational issue behind the miss was the March cyber incident. Stryker said the event disrupted certain IT systems and created a global operational disruption. In plain English, the company’s machinery for processing, shipping, and supporting customer demand did not run at full speed.
That matters because medtech is an execution business. Hospitals and surgical centers do not pause because a vendor has a systems problem. If products are delayed, orders can shift, procedures can be rescheduled, and revenue can move out of the quarter. Stryker said it recovered quickly, but the Q1 numbers show the disruption was real.
Margins also felt the strain. Gross margin slipped to 63.3% from 63.8% a year earlier. Another market summary put adjusted gross margin at 63.6%, down 190 basis points year over year, and adjusted operating margin at 21.1%, down 180 basis points. Either way, the direction is the same: the cyber event did not just ding revenue timing, it also pressured profitability.
So the market is treating this as more than a one-line excuse. A cyber disruption is the kind of event investors can forgive once. However, when it hits a premium stock’s quarter this directly, traders usually cut first and ask for evidence later.
Stryker Financials Show Strength, but the Valuation Leaves Little Room for Error
The interesting part of this selloff is that Stryker’s business is not broken. Net earnings rose to $745M from $654M in the year-ago quarter. The company also maintained full-year 2026 guidance for 8.0%-9.5% organic sales growth and adjusted EPS of $14.90-$15.10.
That is the bull case in one sentence: a bad quarter, not a broken franchise. Stryker remains one of the largest medical device companies in the market, with a $114.40B market cap and strong positions in surgical equipment, hospital products, neurotechnology, and orthopaedics.
Still, valuation is doing a lot of the talking today. SYK trades at about 37.47x earnings, which is a rich multiple for a company that just posted 2.6% sales growth and an earnings miss. Premium stocks work like finely tuned engines. They deliver smooth returns when execution is clean, but they can sputter hard when even one part misfires.
There is also a balance sheet detail worth noting. Cash and equivalents fell to $2.878B at March 31, 2026, from $4.011B at year-end 2025. That does not change the core thesis by itself, but it adds to the sense that Q1 was a quarter investors would rather move past than celebrate.
The longer earnings record also helps frame the reaction. Stryker had beaten EPS estimates in 6 of the previous 7 quarters before this report. That history set a high bar. Therefore, a miss after a long run of steadier execution can hit sentiment harder than the raw numbers alone would imply.
What Today's SYK Selloff Means for Investors
Today’s decline looks like a reset in expectations, not a verdict against the whole company. The market is repricing SYK because a premium multiple and a disrupted quarter are a bad mix, even when full-year guidance stays in place.
That said, the unchanged outlook matters. If Stryker delivers on its $14.90-$15.10 adjusted EPS target and recaptures delayed sales later in 2026, this drop can look more like a confidence crack than a structural break. On the other hand, if growth stays soft in Orthopaedics or the cyber hit lingers in reported results, the stock’s valuation can keep compressing.
For investors, the actionable point is simple: today’s move is tied to a specific earnings miss and cyber-related disruption, not a vague sentiment swing. That makes the next few quarters less about story and more about execution, which is exactly where a medtech leader like Stryker has to earn back the premium.
Stryker (SYK) drops today because Q1 2026 earnings came in below expectations and the March cyber incident left a visible mark on sales growth and margins. The business still has scale, guidance is still intact, and analyst targets remain above the stock price, but a 37.47x P/E means the market is no mood to give execution mistakes a free pass.
SYK is down because Stryker reported a Q1 2026 earnings miss, with adjusted EPS and revenue both coming in below expectations. The March cyber incident also disrupted operations, which hurt sales growth and margins.
+Should I buy SYK stock now?
The stock may appeal to long-term investors who believe Stryker can recover delayed sales and hit its full-year guidance. But near term, the premium valuation and recent execution miss suggest patience may be the better approach.
+Did Stryker lower its full-year guidance?
No, Stryker kept its full-year 2026 guidance unchanged. Management still expects 8.0% to 9.5% organic sales growth and adjusted EPS of $14.90 to $15.10.
+Was the selloff caused by the cyber incident alone?
No, the cyber incident was a major factor, but the bigger trigger was the earnings miss itself. Investors are reacting to both the operational disruption and the weaker-than-expected quarter.
Want the full picture on SYK?
Read the analyst-grade research report — charts, grades, and price targets.
